Bristol-Myers Squibb supporting efforts to help survivors

Bristol-Myers SquibbBristol-Myers Squibb is joining the world community in providing immediate help for survivors of the massive earthquake that struck Haiti on January 12. The company has already shipped a large donation of antibiotics through Project Hope, an organization providing direct relief to disaster victims. In addition, Bristol-Myers Squibb France is sending medicine to help the injured through Tulipe, an organization that facilitates pharmaceutical company donations to provide an emergency response to people in distress as a result of acute health crises, natural disasters or conflicts.

In addition to the medicines the company has shipped or is sending to help the injured, the Bristol-Myers Squibb Foundation will donate a total of $200,000 to three organizations providing disaster relief. The organizations are:

  • The Catholic Medical Mission Board, which has been working in Haiti since 1912 to provide medicines and much needed supplies and support;
  • The American Red Cross, which is giving $10 million to support a number of relief efforts in the country, many already under way; and
  • Partners in Health, which has been working in Haiti since 1987 to address health care needs.

The Bristol-Myers Squibb Foundation will match two-for-one contributions made by employees in the U.S. and Puerto Rico to the following organizations assisting disaster relief efforts in Haiti:

  • AmeriCares
  • American Red Cross
  • CARE
  • Catholic Medical Mission Board
  • Direct Relief International
  • Doctors Without Borders
  • Partners in Health
  • Project Hope
  • Save the Children

Bristol-Myers Squibb will continue to monitor the situation with its relief partners.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

Most Popular Now

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...